LLY - Eli Lilly & Co Stock Price, Fair Value and News

$1033.26-12.86 (-1.23%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

LLY Price Action

Last 7 days

-6.4%

Last 30 days

15.3%

Last 90 days

39.1%

Trailing 12 Months

27.0%

LLY RSI Chart

LLY Valuation

Market Cap

976.8B

Price/Earnings (Trailing)

53.05

Price/Sales (Trailing)

16.44

EV/EBITDA

41.31

Price/Free Cashflow

60.82

LLY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

LLY Fundamentals

LLY Revenue

Revenue (TTM)

59.4B

Rev. Growth (Yr)

53.87%

Rev. Growth (Qtr)

13.13%

LLY Earnings

Earnings (TTM)

18.4B

Earnings Growth (Yr)

475.34%

Earnings Growth (Qtr)

-1.38%

LLY Profitability

EBT Margin

37.87%

Return on Equity

77.2%

Return on Assets

16.02%

Free Cashflow Yield

1.64%

LLY Investor Care

Dividend Yield

0.56%

Dividend/Share (TTM)

5.8

Buy Backs (1Y)

0.41%

Diluted EPS (TTM)

20.44

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	49.0B	53.3B	59.4B	0
2024	35.9B	38.9B	40.9B	45.0B
2023	27.7B	29.5B	32.1B	34.1B
2022	29.3B	29.1B	29.2B	28.5B
2021	25.5B	26.7B	27.8B	28.3B
2020	23.1B	22.9B	23.2B	24.5B
2019	21.6B	21.7B	21.8B	22.3B
2018	20.4B	20.9B	21.3B	21.5B
2017	20.9B	20.6B	20.3B	20.0B
2016	20.2B	20.6B	20.8B	21.2B
2015	19.6B	19.6B	19.7B	20.0B
2014	22.2B	21.2B	20.3B	19.6B
2013	22.6B	22.9B	23.3B	23.1B
2012	24.0B	23.4B	22.7B	22.6B
2011	23.4B	23.9B	24.4B	24.3B
2010	0	0	0	23.1B

Get all data in R, Python etc through our Historical Stock Data APIs

About Eli Lilly & Co

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

CEO	Mr. David A. Ricks
WEBSITE	lilly.com
SECTOR	Healthcare
INDUSTRY	Drug Manufacturers General
EMPLOYEES	39000

Eli Lilly & Co Frequently Asked Questions

What is the ticker symbol for Eli Lilly & Co? What does LLY stand for in stocks?

LLY is the stock ticker symbol of Eli Lilly & Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Eli Lilly & Co (LLY)?

As of Wed Dec 03 2025, market cap of Eli Lilly & Co is 976.83 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LLY stock?

You can check LLY's fair value in chart for subscribers.

Is Eli Lilly & Co a good stock to buy?

The fair value guage provides a quick view whether LLY is over valued or under valued. Whether Eli Lilly & Co is cheap or expensive depends on the assumptions which impact Eli Lilly & Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LLY.

What is Eli Lilly & Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, LLY's PE ratio (Price to Earnings) is 53.05 and Price to Sales (PS) ratio is 16.44. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LLY PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Eli Lilly & Co's stock?

In the past 10 years, Eli Lilly & Co has provided 0.281 (multiply by 100 for percentage) rate of return.